Ask AI
ProCE Banner Activity

FAQs With Expert Perspectives on HER2-Directed ADCs in Breast Cancer: Treatment Selection, Sequencing, and Patient-Centered Care

Clinical Thought

Explore expert perspectives on integrating HER2-directed antibody–drug conjugates (ADCs) into the management of HER2-positive early and metastatic breast cancer. Through a series of questions and answers, faculty discuss patient selection, HER2 testing, treatment sequencing, toxicity management, CNS disease management and practical implications of emerging clinical trial data.

Released: July 01, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity is intended for oncologists, advanced practice providers, pharmacists, nurse practitioners, clinical nurse specialists, nurses, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current evidence and guideline principles to select and sequence HER2-directed therapies across early-stage and metastatic breast cancer 

  • Interpret evolving data on HER2-directed ADCs and integrate key findings into individualized treatment planning for patients with HER2-positive and HER2-expressing disease

  • Improve accuracy in ordering, interpreting, and communicating HER2 IHC and ISH results, including differentiation of HER2-positive, HER2-low, and HER2-ultralow categories and determining when repeat testing is clinically appropriate

  • Identify early indicators of treatment-related events associated with HER2-directed therapies and coordinate multidisciplinary approaches to monitoring, evaluation, and supportive care

Financial Disclosures

Primary Author
Sara A. Hurvitz, MD, FACP: consultant/advisor: Akari, ALX Oncology, Bayer, BeiGene, BeOne, Blueprint, Boundless Bio, BriaCell, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo, Ellipses, EMBioSys, Gilead, Jazz, Lilly Oncology, Luminate, Mersana, Myricx, Prelude Therapeutics, Roche; researcher: AstraZeneca/Daiichi Sankyo, Novartis, Stemline/Menarini; data and safety monitoring board: Alliance Foundation, InClin/Atossa, Quantum Leap, Roche; stocks: ROMTech; other financial or material support: AstraZeneca, Gilead.

Ian Krop, MD, PhD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech, Puma, Seagen.

Adrienne G. Waks, MD: researcher (paid to institution): Genentech, Gilead, Lilly, Merck, TerSera, Verastem; speaker: AstraZeneca, Genentech; consultant/advisor/speaker: Jazz, Johnson & Johnson, Pfizer.